1. Introduction {#sec1}
===============

Small-cell lung cancer (SCLC) accounts for approximately 13--15% of all lung cancers \[[@bib1], [@bib2]\]. Overcoming SCLC remains a large obstacle due to the limited numbers of available treatments and the high proliferative index of this cancer. Thus, thorough exploration of novel treatment strategies is needed.

Recent discovery of relevant gene alterations in non-small-cell lung cancer (NSCLC) has accelerated the development of treatments for patients with NSCLC \[[@bib3]\]. Indeed, a significant increase in survival was demonstrated in patients harboring tumors with such gene alterations and who received genotype-directed therapy \[[@bib4]\]. In the field of SCLC, whole-genome or whole-exome sequence (WES) analysis using next-generation sequencing (NGS) systems has revealed that SCLC also harbors potential targets with gene alterations, including *SOX-2* amplification \[[@bib5]\], mutations in genes responsible for histone modification \[[@bib6], [@bib7], [@bib8]\], and changes genes encoding components of the PI3K/AKT/mTOR pathway \[[@bib9]\], suggesting that novel treatment strategies directed to these targets have potential for treating patients with SCLC. Indeed, several ongoing clinical trials for the treatment of SCLC are examining the role of mutations in the genes encoding components of the PI3K/AKT/mTOR pathway in tumors \[[@bib9]\]. Separately, experiments have shown that classification of gene copy-number aberrations in circulating tumor cells from pretreatment SCLC blood samples can predict chemosensitivity \[[@bib10]\]. However, there is an ongoing debate regarding the utility of comprehensive whole-genome sequencing or WES in clinical use compared with targeted exome sequencing (TES) from the perspectives of data interpretation, time, and cost due to the high volume of information generated by NGS systems \[[@bib11]\].

Recently, various TES studies using clinical samples from patients with SCLC have identified mutations for drug targets \[[@bib12]\], prediction of response to immune checkpoint inhibitors \[[@bib13]\], and gene mutation profiling for diagnosis \[[@bib14]\]. A previous paper demonstrated that *TP53* mutation is associated with unfavorable overall survival (OS) in patients with limited disease (LD)-SCLC \[[@bib15]\]. However, few reports have attempted to validate the clinical utility of TES using a number of surgically resected SCLC tumor specimens in combination with corresponding clinical data, including survival times.

Given these findings, the objective of the present study was two-fold. The first goal was to use our TES system to explore clinically meaningful somatic mutations, including drug targets. The second goal was to assess the relationship between mutation profiles and clinical variables including relapse-free survival (RFS) and/or OS. Together, these results were expected to address whether TES is applicable for clinical use and as an aid in establishing treatment strategies in individual patients with early-stage SCLC.

2. Patients and methods {#sec2}
=======================

2.1. Patient data {#sec2.1}
-----------------

Our eligibility criteria allowed the inclusion of patients with primary SCLC who had undergone complete surgical resection of the primary lung tumor. The study represented patients subjected to surgery from January 2003 through January 2013 at the participating institutions, including either the Fukushima Investigative Group for Healing Thoracic Malignancy (FIGHT) or the Hokkaido Lung Cancer Clinical Study Group Trial (HOT). Written informed consent was obtained only from patients who were still alive at the time of data accrual (from February 2013 through January 2014).

The requirement for consent was waived if the patient had died or could not be contacted. In such cases, investigators of each participating institution were required to provide subjects with a written statement regarding the research in the outpatient department or via a website.

This study was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as Identification Number UMIN000010117; this trial included immunohistochemistry, results of which were reported previously \[[@bib16]\]. The study protocol was approved by the Institutional Review Boards of the respective participating institutions. All individual data were obtained from medical records and de-identified. Each tissue sample was anonymized by assigning a randomized code number. Stages were determined or reclassified according to the seventh edition of the tumor, node, metastasis (TNM) staging system \[[@bib17]\].

This is a retrospective non-interventional genetic association study. Thus, we used the STREGA checklist when writing our report \[[@bib18]\].

2.2. Samples {#sec2.2}
------------

All the cases that were included in the present study met the following criteria: a complete surgical resection of the primary tumors had been performed; and a central re-review confirmed a pathological diagnosis of SCLC or combined SCLC according to the 2004 World Health Organization classification \[[@bib19]\]. Each formalin-fixed paraffin-embedded (FFPE) tissue block was cut so as to yield five sections with 20-μm thicknesses, obtained as a paraffin roll, for use in NGS. Total DNA was obtained from each of the samples. Preparation of DNA and NGS analysis were performed at the Department of Translational Pathology, Hokkaido University Graduate School of Medicine. This is a retrospective observational study. In addition, the number of SCLC patients who underwent surgery is generally limited. Thus, we did not set an appropriate sample size for this study, and instead we attempted to collect as many samples as possible that annotated to clinical data from the institutions.

2.3. TES and mutation profiling {#sec2.3}
-------------------------------

Genomic DNA was extracted from FFPE tissues using QIAamp DNA FFPE Tissue Kits (Qiagen, Hilden, Germany) in accordance with the manufacturer\'s protocol. The quality of genomic DNA was assessed using Qubit dsDNA BR assay kits, a Qubit 2.0 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA), and GeneRead DNA QuantiMIZE Assay Kits (Qiagen). The TruSight Tumor Sequencing Panel (Illumina) was used for library preparation with genomic DNA following the manufacturer\'s instructions. The quality of the libraries was assessed using an Agilent 2100 bioanalyser (Agilent Technologies, Santa Clara, CA, USA) with Agilent DNA 1000 Kits (Agilent Technologies). The libraries were sequenced using MiSeq (Illumina, San Diego, CA, USA) to produce 150-bp paired-end reads. The target exons of 26 cancer-related genes ([Table 1](#tbl1){ref-type="table"}) were loaded on the TruSight Tumor Sequencing Panel (Illumina), which allows detection of hotspot somatic mutations across 14 Kb of exons (21 Kb total length of exons and introns) in genes that are commonly mutated across multiple forms of cancer. The 26 genes selected under the supervision of the College of American Pathologists and The National Comprehensive Cancer Network were all cancer related. Base calling of variant frequency (VF) was performed using Miseq Reporter v2.3 (Illumina) with the default parameter of VF \>3.0%. The paired-end sequence reads that passed the quality-control metrics determined by the pipeline were included in the analysis.Table 1List of genes on TruSight Tumor Sequencing Panel.Table 1*AKT1EGFRGNASNRASSTK11ALKERBB2KITPDGFRATP53APCFBXW7KRASPIK3CABRAFFGFR2MAP2K1PTENCDH1FOXL2METSMAD4CTNNB1GNAQMSH6SRC*[^1]

BAM files obtained from Miseq Reporter v2.3 were processed by the BioReT System (Amelieff, Tokyo, Japan) for analysis of mutations. In the BioReT System, BAM files were realigned and recalibrated with the Genome Analysis Toolkit (GATK) (version 1.6.13), using RealignerTargetCreator, IndelRealigner, CountCovariates, and TableRecalibration. Single-nucleotide variants (SNVs) and small indels were detected using the GATK UnifiedGenotyper, followed by filtering for low-quality variants using the GATK VariantFiltration. All analysis was performed with the default settings except for the minIndelFrac parameter for indel call using GATK UnifiedGenotyper, which was set to 0.05. After variant detection, VCF files were annotated by the SnpEff genetic variant annotation and effect prediction toolbox (version 4.0). Information from the Catalogue of Somatic Mutations in Cancer (COSMIC) database (version 72) and IntOGen (Integrative Onco Genomics, version 1412) were used to annotate the VCF sequences using SnpSift, a package tool of SnpEff, and variants on targeted genes were extracted. SNVs were limited to protein-altering mutations at ≥10% VF with read-depths of \>100. The resulting mutations detected by our TES were stratified into three categories: i) major mutations that were annotated in the COSMIC database and were recognized as driver genes by IntOGen, ii) sub-major mutations that were annotated only in COSMIC, and iii) minor mutations that were not annotated in either COSMIC or IntOGen. All sub-major mutations were synonymous mutations, and all minor mutations were not annotated in the COSMIC database. Therefore, the lesions that were categorized as sub-major and minor mutations were excluded from further consideration in the present study. Next, potential germline variants were manually excluded by reference to gnomAD (<http://gnomad.broadinstitute.org>), a web database that spans 125748 exomes and 15708 genomes from individuals. In an attempt to remove additional germline mutations and to determine the pathogenicity, evidence level, clinical relevance, and description of putative SCLC-associated somatic gene mutations, we consulted several web databases, including ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), CIViC (Clinical Interpretation of Variants in Cancer, <https://civic.genome.wustl.edu/#/home>), OncoKB (A Precision Oncology Knowledge Base, <https://oncokb.org/>), IARC TP53 database (p53.iarc.fr/TP53GeneVariations.aspx), and ICGC Data Portal (<https://dcc.icgc.org/>). The day of last data acquisition from these web databases was March 31, 2020. The analyst (H.M. in the Acknowledgements) was not informed of any data with regard to patient survival and other clinical results.

2.4. Statistical analysis {#sec2.4}
-------------------------

Univariate and multivariate Cox proportional hazard model analyses were performed to examine the association between clinical variables, including gene mutations, and either the RFS or OS. For factors that were significant in univariate analysis, we confirmed the Spearman\'s rank correlation coefficient (r~s~) and avoided entering multiple variables with a high correlation (r~s~ ≥ 0.6) and similar significance. RFS was calculated from the date of surgery to the date of first disease recurrence or death. OS was calculated from the date of surgery to the date of death. Patients who had survived through the observation period were censored at the date for which last available information on status was available. Survival curves were estimated using the Kaplan--Meier method, and differences in survival distributions were evaluated using the log-rank test. All statistical analyses were performed using SPSS version 20 (IBM Corporation, Armonk, NY, USA). A *p* value of \<0.05 was considered statistically significant.

2.5. Data statement {#sec2.5}
-------------------

Raw data of major mutations detected by BioReT System were uploaded in Mendeley Data, V1 ([https://doi.org/10.17632/pczf7nwxp8.1](10.17632/pczf7nwxp8.1){#intref0035}). Synonymous and potential germline mutations were omitted because those mutations were not allowed to be disclosed according to the initial research plan which had been submitted to Institutional Review Boards of the respective participating institutions and the UMIN Clinical Trials Registry.

3. Results {#sec3}
==========

3.1. Patient characteristics {#sec3.1}
----------------------------

A flow chart schematic diagram of the study is provided in [Figure 1](#fig1){ref-type="fig"}. Between January 2003 and January 2013, 157 patients were enrolled from 17 institutions. One hundred twenty-seven tumor samples were obtained from 16 institutions. Of the samples, 48 (37.8%) were unfit for sequencing due to the poor quality of the DNA. Baseline characteristics of the remaining 79 patients are listed in [Table 2](#tbl2){ref-type="table"}. Median age was 69 years, 22 (27.8%) patients were female, and 6 (7.6%) were never-smokers. Eastern Cooperative Oncology Group performance status was 0 in 52 (65.8%) patients. The median maximum tumor diameter was 21 mm. The numbers of patients with SCLC and combined SCLC were 62 (78.5%) and 17 (21.5%), respectively. In terms of pathological stage, 31 cases were IA, 20 were IB, 10 were IIA, 2 were IIB, 13 were IIIA, 1 was IIIB, and 2 were IV. Adjuvant chemotherapy was conducted in 49 (62.0%) patients, including 6 patients who received adjuvant chemoradiotherapy.Figure 1Flow chart diagram. NGS, next-generation sequencing; RFS, relapse-free survival; OS, overall survival.Figure 1Table 2Demographic and clinical characteristics of patients included in this study.Table 2VariablesPatients (n = 79)No.%Age, median (range in years)69 (44--85)Sex Female2227.8 Male5772.2Smoking status Never-smoker67.6 Smoker (current or former)6886.1 Unknown56.3ECOG PS 05265.8 12329.1 Unknown45.1Maximum tumor diameter, median (mm)21 (9--64)Histology SCLC6278.5 Combined SCLC1721.5Clinical stage (TNM, version 7·0) IA5164.6 IB810.1 IIA1113.9 IIB33.8 IIIA56.3 IIIB11.3Pathologic stage (TNM, version 7·0) IA3139.2 IB2025.3 IIA1012.7 IIB22.5 IIIA1316.5 IIIB11.3 IV22.5Adjuvant chemotherapy Yes4962.0 No2936.7 Unknown11.3Comorbidity or past history Interstitial pneumonitis911.4 Other types of cancer2531.6Serum level of LDH \< ULN5873.4 ≥ ULN2126.6Approach VATS4557.0 Open surgery3443.0Type of surgical resection Lobectomy5569.6 Partial resection2227.8 Pneumonectomy22.5PCI Yes67.6 No7189.9 Unknown22.5[^2]

3.2. Mutations detected by TES {#sec3.2}
------------------------------

DNA libraries of 79 samples (62.2%) were successfully subjected to NGS. We detected 38 nonsynonymous somatic *TP53* mutations in 43 (54.4%) patients. A summary of the detected and confirmed mutations in *TP53* is provided in [Figure 2](#fig2){ref-type="fig"}, and the same lists are shown with clinical data in [Table 3](#tbl3){ref-type="table"} and [Table 4](#tbl4){ref-type="table"}. The vast majority of *TP53* mutations corresponded to missense mutations within the DNA-binding domain of the protein, irrespective of the degree of VF. As shown in [Table 3](#tbl3){ref-type="table"}, the *TP53* mutations that we identified included clinically relevant mutations that encoded proteins with Y220C, R248W, R249M, M237I, and R273L substitutions. All of these mutations have been implicated (by clinical or preclinical evidence; as described in CIViC) in other types of malignancies but not in SCLC.Figure 2Distribution of 38 nonsynonymous somatic *TP53* mutations identified in this study. Missense mutations are indicated in blue, nonsense mutations in red, splice site mutations in purple, and frameshift (fs) mutations in orange. Each circle represents a detected mutation. Numbers in the white bar denote the respective exon, and numbers below the bar show corresponding amino acid sequence. For mutation designations, single-letter abbreviations are used for amino acids, except where C \> T and G \> T notations are used to indicate nucleotide substitutions; an asterisk indicates a stop codon.Figure 2Table 3Clinically relevant or potentially clinically relevant somatic mutations of *TP53* mutation and clinical features in our cohort.Table 3ExonMutationVariant patternVFCOSMIC\
IDClinVar annotationCIViC evidence levelOncoKB descriptionClinical relevanceHistologySexAge (years)Smoking statusp-stage6Y220Cmissense0.2871310758Likely pathogenicCOncogenicTP53-independent response to bortezomib in breast cancerSCLCM78unknownIA0.72078SCLCM76everIB0.84699w/SqM60everIV7M237Imissense0.4435510834Likely pathogenicDLikely oncogenicResistance to chemotherapeutic agents in AML cell linesSCLCM65everIA0.69928SCLCM62everIA7R248Wmissense0.281610656Likely pathogenicBLikely oncogenicWorse prognosis in breast cancerSCLCM85everIB7R249Mmissense0.284543871Likely pathogenicBLikely oncogenicBetter response to doxorubicin in breast cancerSCLCM71neverIA8R273Lmissense0.226363675521Likely pathogenicCLikely oncogenicRefractory to platinum-based chemotherapy and shorter time to disease progression and reduction of survival in ovarian cancerw/LaM61unknownIA[^3]Table 4Nonsynonymous somatic mutations of TP53 detected using target exome sequence, potential clinical relevance, and clinical features.Table 4ExonMutationVariant patternVFCOSMIC IDClinVar annotationCiVIC evidence levelOncoKB descriptionOur cohortHistologySexAgeSmoking statusp-stage3--4c.97-1G \> TSplice site0.123891610881NANANAcombined with laF64everIA4R65∗Nonsense0.314381646878PathogenicNALikely oncogenicSCLCM74everIIIA0.23908combined with lnM76everIIA4--5c.376-13C \> TSplice site0.1052644442NANANASCLCM74everIA5c.378C \> TSplice site0.1164844196NANANAcombined with sqF68everIIIA5C135YMissense0.3323110801Likely pathogenicNALikely oncogeniccombined with lnM76everIB5V147Lfs∗23Frameshift0.3443844698NANALikely oncogenicSCLCM70everIB5S149fs∗32Frameshift0.482191324767NANALikely oncogeniccombined with adF63neverIIB5G154VMissense0.38025342245NANALikely oncogenicSCLCM52everIIIA5R158SMissense0.802653970361NANALikely oncogenicSCLCM74everIA5K164∗Nonsense0.5713510750NANALikely oncogenicSCLCF64everIB0.63432SCLCM60everIIA5S183∗Nonsense0.9028110706PathogenicNALikely oncogenicSCLCF61everIB5H179QMissense0.752841649385NANALikely oncogenicSCLCF73neverIIIA6c.560-1G \> TSplice site0.4519443841NANANASCLCM58everIIIA6P190Lfs∗57Frameshift0.2965745320NANALikely oncogenicSCLCM73everIA6H193RMissense0.5222510742Likely pathogenicNALikely oncogenicSCLCM74everIA0.31318SCLCM66everIB6H193YMissense0.3363110672Likely pathogenicNALikely oncogenicSCLCM66everIA6L194PMissense0.28781437527Likely pathogenicNALikely oncogenicSCLCF58everIB6L194RMissense0.46984117647Likely pathogenicNALikely oncogenicSCLCM71everIV0.41548SCLCM69everIA6I195NMissense0.2367444877Likely pathogenicNALikely oncogenicSCLCF73unknownIA6E204∗Nonsense0.38789165087NANALikely oncogeniccombined with sqM74everIB7Y236CMissense0.1300510731Likely pathogenicNALikely oncogeniccombined with sqF68everIIIA7S241FMissense0.3185510812Likely pathogenicNALikely oncogeniccombined with adF63neverIIB7S241YMissense0.687910935Likely pathogenicNALikely oncogenicSCLCM76everIA7G245CMissense0.4077611081Likely pathogenicNALikely oncogeniccombined with adM64everIA7G245DMissense0.774843388189Likely pathogenicNALikely oncogenicSCLCM75everIA7G245RMissense0.7094610957Likely pathogenicNALikely oncogenicSCLCM76everIIA8c.783-1G \> TSplice site0.630826913Likely pathogenicNANASCLCM64everIIIA8F270IMissense0.69492437484Likely pathogenicNALikely oncogenicSCLCM69everIB8E298QMissense0.4548145938NANANAcombined with sqF53everIA8T304IMissense0.5843445128NANANASCLCM77everIB9c.919+1G \> TSplice site0.847192744491Likely pathogenicNANASCLCM75everIIA9T329Hfs∗8Frameshift0.77535002556NANALikely oncogeniccombined with sqM75everIIA10G334VMissense0.1695311514NANAOncogenicSCLCM72everIB0.53128combined with laM62everIB[^4]

The detailed results for five pathogenic or potentially pathogenic somatic mutations in genes other than *TP5*3 that were detected in 5 patients are shown in [Table 5](#tbl5){ref-type="table"} with corresponding clinical data. The mutations included an *AKT1* E17K mutation that has been reported to render tumors sensitive to AZD5363 (capivasertib), an Akt inhibitor \[[@bib20]\]; an *EGFR* E746_A750del mutation that has been reported to render tumors sensitive to an EGFR tyrosine kinase inhibitor \[[@bib21]\], a *FBXW7* R505G mutation that is likely pathogenic \[[@bib22], [@bib23]\]; and *KRAS* G12D and Q61H mutations, both of which are associated with shorter progression-free survival and overall survival by anti-EGFR antibody in colorectal cancer \[[@bib24], [@bib25]\] and responsiveness to MEK inhibitor in combination with cyclin dependent kinase 4/6 inhibitor \[[@bib26], [@bib27]\]. The four of the five patients who harbored these gene mutations were those with combined small-cell carcinoma.Table 5Clinically relevant or potentially clinically relevant somatic mutations except for *TP53* mutation and clinical features in our cohort.Table 5GeneExonMutationVariant patternVFCOSMIC\
IDClinVar annotationCIViC evidence\
levelOncoKB\
Evidence levelClinical relevanceHistologySexAge (years)Smoking statusp-stageAKT14E17Kmissense0.3281733765Pathogenic/Likely pathogenicB3ADrug response to AZD5363 (capivasertib, Akt-i)w/AdF56neverIIIAEGFR19E746_A750 Delindel0.739156223Drug responseA1Longer PFS by EGFR-TKI in NSCLCw/AdF63neverIIBFBXW710R505Gmissense0.3065199604Likely pathogenicNANA (Likely oncogenic)NAw/AdM72everIIIAKRAS2G12Dmissense0.3599521PathogenicBR1, 3A, 4Poor PFS and OS by anti-EGFR Ab in CRC\
Drug response to MEK-i and CDK 4/6-i in CRCSCLCF73neverIIIAKRAS3Q61Hmissense0.183951135364Pathogenic/Likely pathogenicBR1, 3A, 4Poor PFS and OS by anti-EGFR Ab in CRC\
Drug response to MEK-i and CDK 4/6-i in CRCw/LaM61unknownIA[^5]

3.3. Association between somatic TP53 mutations and RFS or OS in SCLC {#sec3.3}
---------------------------------------------------------------------

The median follow-up time of 79 patients was 24.13 months (range, 0.36--119.97). Nonsynonymous somatic mutations of *TP53* were positively associated with RFS \[median, (95% confidence interval): 17.33 months (3.86--30.79) in mutation-positive group vs 10.39 months (6.96--13.82) in mutation-negative group, *p* = 0.042\]. The OS was nominally but not statistically longer in the mutation-positive group compared with mutation-negative group \[median, (95% confidence interval): 44.88 months (20.00--69.76) in mutation-positive group vs 29.06 months (21.64--36.49) in mutation-negative group, *p* = 0.127\] ([Figure 3](#fig3){ref-type="fig"}). Univariate analysis of RFS revealed that this parameter was statistically larger in patients who underwent lobectomy, those with p-stage IA, those who underwent adjuvant chemotherapy, and those who harbored a *TP53* mutation ([Table 6](#tbl6){ref-type="table"}). We did not identify any confounding factors among these four variables using Spearman\'s rank correlation coefficient (data not shown). Multivariate analysis using the four variables demonstrated that *TP53* mutation was an independent factor of prolongation of RFS (hazard ratio: 0.51, 95% confidence interval: 0.29--0.89, *p* = 0.019) ([Table 7](#tbl7){ref-type="table"}). However, univariate and multivariate analysis revealed that OS was not significantly associated with *TP53* mutation ([Table 8](#tbl8){ref-type="table"} and [Table 9](#tbl9){ref-type="table"}).Figure 3Kaplan--Meier curves of relapse-free survival (RFS) (A) and overall survival (OS) (B). Bold lines denote patients with nonsynonymous somatic *TP53* mutations, and dashed lines indicate those without such mutations. Vertical bars indicate the censored cases at the data cutoff point. Mu+, mutation positive; WT, wild type.Figure 3Table 6Univariate analysis of the association between clinical variables and RFS.Table 6VariablesHR95%CI*p* valueAge \<70 years1.240.72--2.130.437Female1.000.55--1.830.990Never-smoker1.010.40--2.540.989ECOG PS: 00.800.44--1.450.464Combined SCLC1.770.94--3.330.078Without history or presence of other types of cancer0.930.51--1.670.799Without IP complication0.950.41--2.230.909Serum level of LDH \< ULN0.630.35--1.120.113VATS approach0.600.35--1.030.064Lobectomy0.450.26--0.780.005p-stage IA0.400.22--0.740.003Adjuvant chemotherapy0.550.31--0.960.036PCI0.340.08--1.390.133*TP53* mutation0.570.33--0.990.044[^6]Table 7Multivariate analysis of the association between clinical variables and RFS.Table 7VariablesHR95%CI*p* valueLobectomy0.460.26--0.800.007p-stage IA0.360.19--0.660.001Adjuvant chemotherapy0.550.32--0.970.038*TP53* mutation0.510.29--0.890.019[^7]Table 8Univariate analysis of the association between clinical variables and OS.Table 8VariablesHR95% CI*p* valueAge \<70 years1.010.55--1.840.983Female0.800.40--1.590.523Never-smoker0.990.35--2.790.987ECOG PS: 00.860.44--1.680.661Combined SCLC1.710.86--3.420.129Without history or presence of other types of cancer0.690.37--1.310.258Without IP complication0.680.29--1.620.383Serum level of LDH \< ULN1.010.51--2.000.986VATS approach0.770.42--1.400.386Lobectomy0.490.27--0.890.020p-stage IA0.410.21--0.820.011Adjuvant chemotherapy0.610.33--1.140.119PCI0.480.12--2.000.313*TP53* mutation0.630.34--1.150.130[^8]Table 9Multivariate analysis of the association between clinical variables and OS.Table 9VariablesHR95% CI*p* valueLobectomy0.460.24--0.850.013p-stage IA0.420.21--0.850.015Adjuvant chemotherapy0.620.33--1.160.135*TP53* mutation0.620.33--1.150.126[^9]

To examine the association between *TP53* mutation and response to chemotherapy, we generated Kaplan--Meier curves for patients with and without *TP53* mutations, performing this analysis separately for patients who did ([Figure 4](#fig4){ref-type="fig"}A) and did not ([Figure 4](#fig4){ref-type="fig"}B) receive adjuvant chemotherapy. RFS was nominally, but not significantly, prolonged in patients with *TP53* mutations compared with those lacking *TP53* mutations, both in the cohort of patients who underwent adjuvant chemotherapy (median: 54.74 months \[95% CI, NR (not reached)--NR\] vs 12.33 months \[95% CI, 3.33--21.33\], p = 0.070) and in the cohort of patients who did not receive adjuvant chemotherapy (median: 15.42 months \[95% CI, 11.63--19.21\] vs 6.90 months \[95% CI, 1.63--12.17\], *p* = 0.415).Figure 4Kaplan--Meier curves of relapse-free survival (RFS) in patients who underwent adjuvant chemotherapy (A) and those who did not (B). Bold lines denote patients with nonsynonymous somatic *TP53* mutations, and dashed lines indicate those without such mutations. Vertical bars indicate the censored cases at the data cutoff point. Mu+, mutation positive; WT, wild type.Figure 4

4. Discussion {#sec4}
=============

We analyzed hotspot mutations in 26 cancer-related genes using a TES system in tumors from patients with surgically resected SCLC. Specifically, we found 54.4% of the patients harbored tumors containing *TP53* nonsynonymous somatic mutations. Among these lesions, we found several clinically relevant somatic mutations. However, the development of treatments that target TP53 has not been clinically successful. In addition, as shown in [Table 5](#tbl5){ref-type="table"}, only five pathogenic or potentially pathogenic somatic mutations in genes other than *TP53* were identified. These results suggested that the limited number of genes included in the cancer panel in the present study were not sufficient for practical identification of novel drug targets.

All of the five clinically relevant mutations of *TP53*, which are shown in [Table 3](#tbl3){ref-type="table"}, have been reported to have a relationship with prognosis, sensitivity or insensitivity to chemotherapy. These previous *TP53* results were described in the literature in the context of acute myeloid leukemia (AML), or breast or ovarian cancer, but not in the context of SCLC.

The existence or the number of *TP53* mutations has been demonstrated to be associated with unfavorable OS in patients with LD-SCLC \[[@bib15]\], lung adenocarcinoma \[[@bib28]\], NSCLC \[[@bib29], [@bib30]\], and other malignancies \[[@bib31], [@bib32], [@bib33]\]. However, in our study, nonsynonymous somatic mutations of *TP53* were positively associated with RFS and nominally with improved OS. The distinct associations between *TP53* mutations and survival may be attributable to basic TP53 biology.

*TP53* is known as a master transcription factor and critical tumor suppressor. Wild-type (WT) *TP53* in cancer has generally been described as an inducer of cell cycle arrest and apoptosis by cellular stress such as chemotherapy. In many cancer types, a strong correlation exists between the presence of *TP53* mutations and reduced responses to chemotherapeutic agents and, thus, a poor prognosis \[[@bib34], [@bib35]\]. We, therefore, examined whether chemotherapy might be associated with the shorter survival of patients with *TP53* mutation than those without in our cohort. However, there was no difference in RFS between patients with *TP5*3 WT and those with *TP53* mutation irrespective of chemotherapy ([Figure 4](#fig4){ref-type="fig"}), suggesting that the difference in RFS between patients with *TP5*3 WT and those with *TP53* mutation might be due to other factors.

An enormous amount of research has established multiple aspects of *TP53* functionality and its network in the context of cells \[[@bib36]\]. We summarized the potential pathobiological factors of *TP53* which were expected and lacking in the present study.

i\) *TP53* target: conversely, *TP5*3 has been demonstrated to regulate proteins that exert an anti-apoptotic potential. Anti-apoptotic *TP53* targets include genes related to DNA repair, cell cycle control, oxidative stress response, co-transcriptional factors, TP53-binding proteins, and MAPK signaling. The expression levels and duration of occupancy of these targets in tumor cells are context dependent \[[@bib37]\].

ii\) Tumor microenvironment: senescence-associated secretory phenotype (SASP) is a phenotype associated with senescent cells regulated by specific transcription factors including *TP53*, and can be responsible for chronic inflammation and age-linked diseases including cancer \[[@bib38]\]. *TP53*-driven SASP in tumor stroma can create a tumor-suppressive immune milieu that influences the incidence of cancer \[[@bib39], [@bib40]\]; however, the SASP can mediate chronic inflammation and stimulate the growth and survival of tumor cells in a cell context-dependent manner \[[@bib41], [@bib42]\]. The *TP5*3 WT in our patients might induce the SASP, thereby creating an environment that promotes tumor proliferation.

iii\) Cancer immunity: *TP53* regulates the expression of the natural-killer group 2, member D ligands, either positively or negatively as a transcriptional target through the upregulation of miR-34a. The miR34 family suppresses programmed death ligand 1 expression, an inhibitor of T cell activity \[[@bib43]\]. These results suggest that exploring the difference in the tumor immune microenvironment within our SCLC samples with or without *TP53* mutation might be important.

iv\) Autophagy regulation: *TP53*-driven cellular senescence may be supported by activation of autophagy \[[@bib44]\]. In some settings, autophagy has the potential to delay apoptosis by reducing the levels of the pro-apoptotic BH3-only protein PUMA \[[@bib45]\]. The dual roles of autophagy in cancer, including tumor progression and promotion, are also cell reliant \[[@bib46]\]. Autophagy regulation and related factors might affect the survival of our SCLC patients.

v\) Cancer stem cell (CSC)-like features: CSCs are associated with aggressive cancer behavior, metastatic progression, resistance to therapy and relapse. CD133^+^ cancer stem-like cells in SCLC are highly tumorigenic and resistant to chemotherapy \[[@bib47], [@bib48], [@bib49]\]. Although *TP53* was previously reported to transcriptionally suppress CD133 expression \[[@bib50]\], *TP53* may function with different transcription factors in colorectal cancer to maintain the stem cell properties \[[@bib51]\], which may be independent of the tumor suppressor role of *TP53*. *TP5*3 WT in early-stage SCLC might correlate with the nature of CSC. Examining the expression of CSC-like markers including CD133 in combination with *TP5*3 WT/mutation, may be one of the methods for clarifying the reason for differences in RFS.

vi\) Intratumor genetic heterogeneity: a previous report described that cancer cells with *TP5*3 WT and *TP53* mutation resided as different clusters in the same tumor sample of prostate cancer \[[@bib52]\]. The use of surgical specimens, as in the present study, can avoid the clonal heterogeneity that is observed in small biopsy samples, an aspect that is a strength of our study.

This study has several limitations that require cautious interpretation; we consider three of those limitations here. First, paired normal tissues could not be obtained for the specimens examined in our study. Thus, it remains possible that some of the mutations classified as somatic events in the present study may in fact be germline mutations in this Japanese cohort, although we screened for such lesions using various web databases.

Second, our TES system does not cover all exons of each of the 26 template genes, which might have compromised our ability to assess less-frequent, non-canonical gene mutations.

Third, ours was a retrospective observational study recruiting a heterogeneous population with a variety of treatments before and after surgery and representing a limited number of patients. Thus, it is possible that we would not have been able to detect precise associations between gene mutation profiles and survival.

In conclusion, TES of cancer-related genes by NGS and comparison with web databases, as used in this study, permitted us to identify several meaningful gene mutations that were predicted to alter drug response and survival in SCLC. However, our analysis surveyed a limited number of clinically relevant genes. Thus, an investigation of a larger gene panel in the TES system is recommended. The OncoGuide NCC Oncopanel System (Sysmex Corporation, Kobe, Japan), a panel that covers 114 genes, and FoundationOne (Foundation Medicine Inc. Cambridge, MA, USA), a panel that covers 324 genes, both received insurance coverage for use in cancer genome profiling in Japan in June 2019. Accumulation of gene alteration data and correlation with various clinical variables by these panels for research use may facilitate exploration of drug targets and promote reverse-translational research, including that on *TP53* mutations. These efforts are expected eventually to assist the development of precision treatments for patients with SCLC.
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[^1]: Gene products: *ALK*, anaplastic lymphoma kinase; *APC*, adenomatous polyposis coli; *CDH1*, cadherin 1; *CTNNB1*, catenin beta 1; *EGFR*, epidermal growth factor receptor; *FBXW7*, F-box and WD repeat domain containing 7; *FGFR2*, fibroblast growth factor receptor 2; *FOXL2*, forkhead box L2; *GNAQ*, guanine nucleotide binding protein, Q polypeptide; *GNAS*, guanine nucleotide binding protein, alpha stimulating; *MSH6*, MutS homolog 6; *PDGFRA*, platelet-derived growth factor receptor, alpha; *PIK3CA*, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha; *PTEN*, phosphatase and tensin homologue; *STK11*, serine/threonine kinase 11, also known as liver kinase B1 (LKB1); *TP53*, tumor protein P53.

[^2]: ECOG PS, Eastern Cooperative Oncology Group performance status; SCLC, small-cell lung cancer; TNM, tumor-node-metastasis; LDH, lactate dehydrogenase; ULN, upper limit of normal range; TNM, tumor-node-metastasis; VATS, video-assisted thoracoscopic surgery; PCI, prophylactic cranial irradiation.

[^3]: VF, variant frequency; Age, age at diagnosis; p-stage, pathological stage; SCLC, small-cell lung cancer; w/Sq, combined with squamous cell carcinoma; AML, acute myeloid leukemia; w/La, combined with large cell carcinoma; CIViC evidence level B, clinical: clinical trials or other primary patient data supports association; CIViC evidence level C, case study: individual case reports from clinical journals; CIViC evidence level D, preclinical: *in vivo* or *in vitro* models support association.

[^4]: VF, variant frequency; COSMIC, Catalogue of Somatic Mutations in Cancer; ID, identification; p-stage, pathological stage; NA, not available; la, large cell carcinoma; SCLC, small-cell lung cancer; ln, large cell neuroendocrine carcinoma; sq, squamous cell carcinoma; ad, adenocarcinoma. For mutation designations, single-letter abbreviations are used for amino acids, except where C \> T and G \> T notations are used to indicate nucleotide substitutions; an asterisk indicates a stop codon.

[^5]: VF, variant frequency; Age, age at diagnosis; p-stage, pathological stage; Akt-i, Akt inhibitor; w/Ad, combined with adenocarcinoma; EGFR, epidermal growth factor receptor; indel, insertion and deletion; PFS, progression free survival; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; FBXW7, F-box and WD repeat domain containing 7; NA, not available; OS, overall survival; CRC, colorectal cancer; Ab, antibody; MEK-i, MEK inhibitor; CDK 4/6-i, cyclin dependent kinase 4/6 inhibitor; SCLC, small cell lung cancer; w/La, combined with large cell carcinoma.

[^6]: RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; SCLC, small-cell lung cancer; IP, interstitial pneumonitis; LDH, lactate dehydrogenase; ULN, upper limit of normal range; VATS, video-assisted thoracoscopic surgery; p-stage, pathological stage; PCI, prophylactic cranial irradiation. Cox proportional hazard model analysis was used to obtain p values.

[^7]: RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; p-stage, pathological stage; Cox proportional hazard model analysis was used to obtain p values.

[^8]: OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; SCLC, small-cell lung cancer; IP, interstitial pneumonitis; LDH, lactate dehydrogenase; ULN, upper limit of normal range; VATS, video-assisted thoracoscopic surgery; p-stage, pathological stage; PCI, prophylactic cranial irradiation. Cox proportional hazard model analysis was used to obtain p values.

[^9]: OS, overall survival; HR, hazard ratio; CI, confidence interval; p-stage, pathological stage. Cox proportional hazard model analysis was used to obtain p values.
